LDS/Medical Tests/Oncotype DX, Prostate Cancer

Oncotype DX, Prostate Cancer

Certain genes are associated with cancers and the expression of these genes is related to the behavior of cancer, its growth, and spread. Oncotype DX is a gene expression assay in which 21 genes are assayed among which 16 genes are related to breast cancer and 5 are reference genes. The RNA extracted from the FFPE (formalin-fixed paraffin-embedded) tissue is subjected to the RT-PCR and on the basis of evaluating the gene expression profile and using a proprietary algorithm a recurrence score (0-100) is determined. The assayed gene is normalized to the expression of the panel of five reference genes.

The 16-breast cancer related genes, comprise five groups: Proliferation genes (Ki67, STK15, Surviving, CCNB1, MYBL2), Invasion genes (MMP11, CTSL2), HER2 genes (GRB2, HER2), Estrogen genes (ER, PGR, BCL2, SCUBE3) and other cancer related genes that are prognostic markers (GSTM1, CD68, BAG1).

The recurrence score is graded as low (<18), intermediate (18-31), or high risk (>31) of distant recurrence within 10 years in node-negative, ER-positive breast cancer patients treated with tamoxifen. This test also helps to predict chemotherapy benefit in patients with early-stage (stage I, II, or IIIa) breast cancer having node-negative/positive states, ER-positive, and HER2-negative disease. The higher the recurrence score, the higher the potential benefit of chemotherapy treatment relative to adverse effects. The lower the recurrence score, lower the benefit of chemotherapy treatment relative to adverse effects. Therefore, the Oncotype DX can inform treatment decisions and reduces adjuvant chemotherapy use in routine clinical practice.

  • To evaluate the risk of distant recurrence in early-stage breast cancer patients
  • To predict the beneficial effect of chemotherapy in patients with early-stage (stage I, II, or IIIa) breast cancer having node-neg/pos, ER-positive, HER2-negative disease

For men > 50 years of age:

  • Recurrence score <25 - Low risk of recurrence. Prone to adverse effects of chemotherapy and less beneficial effects.
  • Recurrence score 25-100 – High risk of recurrence. Benefits of chemotherapy is greater than the adverse effects.

For men < 50 years of age:

  • Recurrence score0-15: Low risk of recurrence. Prone to adverse effects of chemotherapy and less beneficial effects.
  • Recurrence score 16-20: Low to medium risk of recurrence. Prone to adverse effects of chemotherapy and less beneficial effects.
  • Recurrence score <25: Moderate risk of recurrence. Benefits of chemotherapy is greater than the adverse effects.
  • Recurrence score <25: High risk of recurrence. Benefits of chemotherapy is greater than the adverse effects.

Negative, No pathogenic genes detected

Gene expression by RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction).

FFPE (Formalin-fixed paraffin embedded) tumor tissue

Stability

  • Stable at room temperature and refrigerator for a longer period.

Prostate biopsy, Hematoxylin and Eosin staining, immunohistochemistry.

2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Mol Diagn Ther. 2020 Oct;24(5):621-632. [PMID: 32613290]
  • Cancer. 2010 Jul 1;116(13):3112-8. [PMID: 20564629]
  • Cancer. 2010 Nov 15;116(22):5161-7. [PMID: 20665886]
  • Eur J Surg Oncol. 2017 May;43(5):921-930. [PMID: 28087099]
  • J Med Econ. 2022 Jan-Dec;25(1):591-604. [PMID: 35416089]
  • Bland KI, Copeland EM, Klimberg VS, Gradishar WJ. The Breast: Comprehensive Management of Benign and Malignant Diseases.5th ed Elsevier Health Sciences; 2009 Jun 29.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login